Sign up to access all valuation multiples
Beijing Tiantan Biological Products Corp Ltd uses healthy human plasma and specifically immunized human plasma as raw materials and adopts genetic recombination technology to develop and produce blood products and engage in the blood product business. The company's main products include human albumin, human immunoglobulin (pH4) for intravenous injection, human hepatitis B immunoglobulin, human immunoglobulin, human rabies immunoglobulin, human histamine immunoglobulin, and others.
1998
5.3K+
LTM Revenue $920M
LTM EBITDA $376M
$5.3B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Beijing Tiantan has a last 12-month revenue (LTM) of $920M and a last 12-month EBITDA of $376M.
In the most recent fiscal year, Beijing Tiantan achieved revenue of $840M and an EBITDA of $402M.
Beijing Tiantan expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Beijing Tiantan valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $920M | XXX | $840M | XXX | XXX | XXX |
| Gross Profit | $448M | XXX | $459M | XXX | XXX | XXX |
| Gross Margin | 49% | XXX | 55% | XXX | XXX | XXX |
| EBITDA | $376M | XXX | $402M | XXX | XXX | XXX |
| EBITDA Margin | 41% | XXX | 48% | XXX | XXX | XXX |
| EBIT | $339M | XXX | $351M | XXX | XXX | XXX |
| EBIT Margin | 37% | XXX | 42% | XXX | XXX | XXX |
| Net Profit | $209M | XXX | $216M | XXX | XXX | XXX |
| Net Margin | 23% | XXX | 26% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of August 29, 2025, Beijing Tiantan's stock price is CNY 20 (or $3).
Beijing Tiantan has current market cap of CNY 39.6B (or $5.5B), and EV of CNY 37.9B (or $5.3B).
See Beijing Tiantan trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5.3B | $5.5B | XXX | XXX | XXX | XXX | $0.11 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of August 29, 2025, Beijing Tiantan has market cap of $5.5B and EV of $5.3B.
Beijing Tiantan's trades at 6.3x EV/Revenue multiple, and 13.1x EV/EBITDA.
Equity research analysts estimate Beijing Tiantan's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Beijing Tiantan has a P/E ratio of 26.4x.
See valuation multiples for Beijing Tiantan and 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $5.5B | XXX | $5.5B | XXX | XXX | XXX |
| EV (current) | $5.3B | XXX | $5.3B | XXX | XXX | XXX |
| EV/Revenue | 5.7x | XXX | 6.3x | XXX | XXX | XXX |
| EV/EBITDA | 14.0x | XXX | 13.1x | XXX | XXX | XXX |
| EV/EBIT | 15.6x | XXX | 15.0x | XXX | XXX | XXX |
| EV/Gross Profit | 11.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | 26.4x | XXX | 25.6x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -152.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBeijing Tiantan's last 12 month revenue growth is 13%
Beijing Tiantan's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $20K for the same period.
Beijing Tiantan's rule of 40 is 53% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Beijing Tiantan's rule of X is 74% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Beijing Tiantan and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 13% | XXX | 13% | XXX | XXX | XXX |
| EBITDA Margin | 41% | XXX | 48% | XXX | XXX | XXX |
| EBITDA Growth | 7% | XXX | 14% | XXX | XXX | XXX |
| Rule of 40 | 53% | XXX | 61% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 74% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $20K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 0% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 2% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 13% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Beijing Tiantan acquired XXX companies to date.
Last acquisition by Beijing Tiantan was XXXXXXXX, XXXXX XXXXX XXXXXX . Beijing Tiantan acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was Beijing Tiantan founded? | Beijing Tiantan was founded in 1998. |
| Where is Beijing Tiantan headquartered? | Beijing Tiantan is headquartered in China. |
| How many employees does Beijing Tiantan have? | As of today, Beijing Tiantan has 5.3K+ employees. |
| Is Beijing Tiantan publicy listed? | Yes, Beijing Tiantan is a public company listed on SHG. |
| What is the stock symbol of Beijing Tiantan? | Beijing Tiantan trades under 600161 ticker. |
| When did Beijing Tiantan go public? | Beijing Tiantan went public in 1998. |
| Who are competitors of Beijing Tiantan? | Similar companies to Beijing Tiantan include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Beijing Tiantan? | Beijing Tiantan's current market cap is $5.5B |
| What is the current revenue of Beijing Tiantan? | Beijing Tiantan's last 12 months revenue is $920M. |
| What is the current revenue growth of Beijing Tiantan? | Beijing Tiantan revenue growth (NTM/LTM) is 13%. |
| What is the current EV/Revenue multiple of Beijing Tiantan? | Current revenue multiple of Beijing Tiantan is 5.7x. |
| Is Beijing Tiantan profitable? | Yes, Beijing Tiantan is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Beijing Tiantan? | Beijing Tiantan's last 12 months EBITDA is $376M. |
| What is Beijing Tiantan's EBITDA margin? | Beijing Tiantan's last 12 months EBITDA margin is 41%. |
| What is the current EV/EBITDA multiple of Beijing Tiantan? | Current EBITDA multiple of Beijing Tiantan is 14.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
